BioSpace News Archive

Biond Biologics Ltd. today announced that Tehila Ben Moshe will be presenting therapeutics targeting ILTs (also known as LILRBs) at the LILRB/ILT Virtual Symposium titled: “Deep Dive into “Myeloid Checkpoint” Therapeutics in Cancer”, hosted by Raymond James on April 26, 2022.

Leading diagnostic and therapeutic medical technology company, Laborie Medical Technologies Corp. (Laborie), announced that it has completed the acquisition of GI Supply.

REGENXBIO Inc. (Nasdaq: RGNX) today announced it will present in a fireside chat at Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Tuesday, April 26, 2022 at 8:30 a.m. ET.

STAAR Surgical Company today announced that it will release financial results for the first quarter ended April 1, 2022 on Wednesday, May 4, 2022 after the market close.

Clover Biopharmaceuticals, Ltd. today announced additional data from SPECTRA, a global pivotal Phase 2/3 clinical trial, that shows SCB-2019 (CpG 1018/Alum) provides significant incremental protection against COVID-19.

Clinical benefit again observed for OTO-413 versus placebo for multiple efficacy endpoints based on responder analysis at both Days 57 and 85 Results support clinical activity and tolerability findings from previous Phase 1/2 trial Enrollment in higher dose cohorts is ongoing with results expected in second half of 2022 Otonomy expects to initiate full dose-ranging Phase 2 efficacy trial by the end of 2022 Management will review results during a conference call today at 8:30 a.m. E

Arcturus Therapeutics Holdings Inc. today shared topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, Arcturus’ self-amplifying mRNA vaccine candidate against COVID-19 disease caused by the SARS-CoV-2 virus.

Eyenovia, Inc. today announced that Dr. Sean Ianchulev, Chairman, Chief Executive Officer and Chief Medical Officer, will deliver a presentation at Eyecelerator, which is being held on Thursday, April 21 in Washington, DC.

ProSomnus Sleep Technologies today announced that it will showcase its precision Oral Appliance Therapy (OAT) devices in three poster abstracts at the 2022 American Academy of Dental Sleep Medicine (AADSM) Annual Meeting , being held from May 13-15 in Dallas, Texas.

Manasi Sinha Jaiman, M.D., M.P.H., who was recently appointed Chief Medical Officer at Viacyte Inc., will participate in the 15th International Conference on Advanced Technologies & Treatments for Diabetes’ (ATTD) session, Utility of PROs in Therapy Development for Type 1 Diabetes: Putting the End-User Upfront.